PPI Marketers Target Patients Leaving COX-2s For NSAIDs
This article was originally published in The Tan Sheet
Executive Summary
Proton pump inhibitor marketers are poised to benefit from potential cardiovascular risk warnings for COX-2 inhibitors that could increase the migration of arthritis patients to traditional NSAIDs
You may also be interested in...
“Black Box” Gives Black Eye To Prospects For COX-2 Ads Returning
While an FDA advisory committee voted strongly in favor of allowing continued marketing of Celebrex (celecoxib), the panel's recommendations for warnings diminish the prospects of renewed DTC marketing
Prevacid NapraPAC Scripts Suggest PPI/NSAID Combos May Thrive Post-Vioxx
TAP's Prevacid NapraPAC is among the early winners in the arthritis market following the withdrawal of Merck's Vioxx, IMS Health data suggest
AstraZeneca Nexium Cleared For Lowering Risk Of NSAID-Related Ulcers
A supplemental approval for Nexium will allow AstraZeneca to position the proton pump inhibitor as an alternative to switching patients to a COX-2 to reduce the risk of gastric ulcers associated with continuous NSAID therapy